Imbalance of angiogenesis in diabetic complications: The mechanisms

International Journal of Preventive Medicine

Volumn 3, Issue 12, 2012, Pages 827-838

  Tahergorabi, Zoya ^a   Khazaei, Majid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Diabetes mellitus; Diabetic complications; Macro vascular; Micro vascular

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

AGING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; EXERCISE; FAT INTAKE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALIGNANT NEOPLASTIC DISEASE; MICROANGIOPATHY; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; POPULATION RESEARCH; PREVALENCE; REVIEW; VASCULAR DISEASE; WOUND HEALING IMPAIRMENT;

EID: 84871708650     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: 10.4103/2008-7802.104853     Document Type: Review

References (106)

1. GoldenSH. Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. Am J Cardiol 2011;108:59B-67.
2. EdwardsMS, WilsonDB, CravenTE, StaffordJ, FriedLF, WongTY, et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: The Cardiovascular Health Study. Am J Kidney Dis 2005;46:214-24.
3. JeerakathilT, JohnsonJA, SimpsonSH, MajumdarSR. Short-term risk for stroke is doubled in persons with newly treated type2 diabetes compared with persons without diabetes: Apopulation-based cohort study. Stroke 2007;38:1739-43.
4. RoglicG, UnwinN, BennettPH, MathersC, TuomilehtoJ, Nag S, et al. The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5.
5. DixonJB. Obesity and diabetes: The impact of bariatric surgery on type-2 diabetes. World J Surg 2009;33:2014-21.
6. LiS, ZhaoJH, LuanJ, LangenbergC, LubenRN, Khaw KT, et al. Genetic predisposition to obesity leads to increased risk of type2 diabetes. Diabetologia 2011;54:776-82.
7. LeibsonCL, WilliamsonDF, Melton LJ 3rd, Palumbo PJ, Smith SA, Ransom JE, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care 2001;24:1584-9.
8. IDF. IDF diabetes atlas. 4thed. Brussels(Belguim): International Diabetes Federation; 2009.
9. TwiggSM, ChenMM, JolyAH, ChakrapaniSD, TsubakiJ, KimHS, et al. Advanced glycosylation end products up-regulate connective tissue growth factor(insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: Apotential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001;142:1760-9.
10. XueY, LimS, BrakenhielmE, CaoY. Adipose angiogenesis: Quantitative methods to study microvessel growth, regression and remodeling in vivo. Nat Protoc 2010;5:912-20.
11. KhazaeiM, SalehiE, RashidiB. Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Int J Pept 2012;2012:637212.
12. KhazaeiM, SalehiE, RashidiB, JavanmardSH, Fallahzadeh AR. Role of peroxisome proliferator-activated receptor beta agonist on angiogenesis in hindlimb ischemic diabetic rats. JDiabetes Complications 2012;26:137-40.
13. MartinA, KomadaMR, SaneDC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003;23:117-45.
14. Goodwin AM. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 2007;74:172-83.
15. BremH, JacobsT, VileikyteL, WeinbergerS, GibberM, Gill K, et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003;11:85-92.
16. SassoFC, TorellaD, CarbonaraO, EllisonGM, TorellaM, Scardone M, etal. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type2 diabetic patients with chronic coronary heart disease. JAm Coll Cardiol 2005;46:827-34.
17. Available from: http://www.roche.com/pages/facets/3/diabetes_2.jpg. [Last accessed on 2012Oct24].
18. AntonettiDA, KleinR, GardnerTW. Diabetic retinopathy. NEngl J Med 2012;366:1227-39.
19. KleinR, KleinBE. Are individuals with diabetes seeing better?: Along-term epidemiological perspective. Diabetes 2010;59:1853-60.
20. KleinR, LeeKE, GangnonRE, KleinBE. The 25-year incidence of visual impairment in type1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2010;117:63-70.
21. SuEJ, FredrikssonL, SchielkeGP, ErikssonU, Lawrence DA. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost 2009;7:155-8.
22. HawkinsBT, DavisTP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173-85.
23. PournarasCJ, Rungger-BrandleE, RivaCE, HardarsonSH, StefanssonE. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008;27:284-330.
24. GardnerTW, LarsenM, GirachA, ZhiX. Diabetic macular oedema and visual loss: Relationship to location, severity and duration. Acta Ophthalmol 2009;87:709-13.
25. BaiY, MaJX, GuoJ, WangJ, ZhuM, ChenY, et al. Muller cell-derived VEGF is a significant contributor to retinal neovascularization. JPathol 2009;219:446-54.
26. WangJ, XuX, ElliottMH, ZhuM, LeYZ. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010;59:2297-305.
27. WirostkoB, WongTY, SimoR. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008;27:608-21.
28. HarhajNS, FelinskiEA, WolpertEB, SundstromJM, GardnerTW, AntonettiDA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006;47:5106-15.
29. MurakamiT, FelinskiEA, AntonettiDA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. JBiol Chem 2009;284:21036-46.
30. AielloLP, DavisMD, GirachA, Kles KA, Milton RC, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30.
31. NavaratnaD, McGuirePG, MenicucciG, DasA. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007;56:2380-7.
32. EngeM, Bjarnegård M, GerhardtH, GustafssonE, KalénM, AskerN, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002;21:4307-16.
33. GeraldesP, Hiraoka-YamamotoJ, MatsumotoM, ClermontA, LeitgesM, MaretteA, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298-306.
34. HotamisligilGS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
35. Wilkinson-BerkaJL, TanG, JaworskiK, MillerAG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009;104:124-33.
36. DemircanN, SafranBG, SoyluM, OzcanAA, SizmazS. Determination of vitreous interleukin-1(IL-1) and tumour necrosis factor(TNF) levels in proliferative diabetic retinopathy. Eye(Lond) 2006;20:1366-9.
37. FelinskiEA, CoxAE, PhillipsBE, AntonettiDA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp Eye Res 2008;86:867-78.
38. GuoM, RicardoSD, DeaneJA, ShiM, Cullen-McEwenL, BertramJF. Astereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. JAnat 2005;207:813-21.
39. NakagawaT, KosugiT, HanedaM, RivardCJ, LongDA. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009;58:1471-8.
40. HohensteinB, HausknechtB, BoehmerK, RiessR, BrekkenRA, HugoCP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006;69:1654-61.
41. McGinnS, SaadS, PoronnikP, PollockCA. High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol Endocrinol Metab 2003;285:E708-17.
42. OsterbyR, BangstadHJ, NybergG, RudbergS. On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy. Virchows Arch 2001;438:129-35.
43. KhazaeiM, FallahzadehAR, SharifiMR, AfsharmoghaddamN, JavanmardSH, SalehiE. Effects of diabetes on myocardial capillary density and serum angiogenesis biomarkers in male rats. Clinics(Sao Paulo) 2011;66:1419-24.
44. FallahzadehAR, KhazaeiM, SharifiMR. Restoration of angiogenesis by enalapril in diabetic hindlimb ischemic rats. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:137-42.
45. NakagawaT, SatoW, GlushakovaO, HeinigM, ClarkeT, Campbell-ThompsonM, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. JAm Soc Nephrol 2007;18:539-50.
46. WoolfAS, GnudiL, LongDA. Roles of angiopoietins in kidney development and disease. JAm Soc Nephrol 2009;20:239-44.
47. YuanHT, KhankinEV, KarumanchiSA, ParikhSM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009;29:2011-22.
48. De VrieseAS, TiltonRG, ElgerM, StephanCC, KrizW, LameireNH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. JAm Soc Nephrol 2001;12:993-1000.
49. CarmelietP, StorkebaumE. Vascular and neuronal effects of VEGF in the nervous system: Implications for neurological disorders. Semin Cell Dev Biol 2002;13:39-53.
50. KimH, ParkJS, ChoiYJ, KimMO, HuhYH, KimSW, et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells 2009;27:1686-96.
51. MalikRA, TesfayeS, NewrickPG, WalkerD, RajbhandariSM, SiddiqueI, etal. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48:578-85.
52. YagihashiS, YamagishiSI, Wada RiR, BabaM, HohmanTC, Yabe-Nishimura C, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448-58.
53. AltanVM. The pharmacology of diabetic complications. Curr Med Chem 2003;10:1317-27.
54. LazaroviciP, MarcinkiewiczC, LelkesPI. Cross talk between the cardiovascular and nervous systems: Neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor(NGF)-implications in drug development. Curr Pharm Des 2006;12:2609-22.
55. IiM, NishimuraH, KusanoKF, QinG, YoonYS, Wecker A, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93-102.
56. ZacchignaS, LambrechtsD, CarmelietP. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008;9:169-81.
57. VincentAM, RussellJW, LowP, FeldmanEL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004;25:612-28.
58. GaleanoM, TorreV, DeodatoB, CampoGM, ColonnaM, Sturiale A, et al. Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. Surgery 2001;129:467-77.
59. TrautnerC, HaastertB, SpraulM, GianiG, BergerM. Unchanged incidence of lower-limb amputations in a German City, 1990-1998. Diabetes Care 2001;24:855-9.
60. TrautnerC, HaastertB, GianiG, BergerM. Amputations and diabetes: Acase-control study. Diabet Med 2002;19:35-40.
61. LermanOZ, GalianoRD, ArmourM, LevineJP, GurtnerGC. Cellular dysfunction in the diabetic fibroblast: Impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003;162:303-12.
62. MaruyamaK, AsaiJ, IiM, ThorneT, LosordoDW, D'Amore PA. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol 2007;170:1178-91.
63. VerheulHM, PinedoHM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85.
64. KolluruGK, BirSC, KevilCG. Endothelial dysfunction and diabetes: Effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012;2012:918267.
65. KusumantoYH, van WeelV, MulderNH, SmitAJ, van den DungenJJ, HooymansJM, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: Adouble-blind randomized trial. Hum Gene Ther 2006;17:683-91.
66. MohammadG, pandey HP, TripathiK. Diabetic wound healing and its angiogenesis with special reference to nanoparticles. Dig J Nanomater Biostructures 2008;3:203-8.
67. MishraVK, MohammadG, MishraSK. Down regulation of telomerase activity may enhance by Nanoparticle mediated curcumin delivery. Dig J Nanomater Biostructures 2008;3:163-9.
68. Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev 2008;32:190-9.
69. VigneriP, FrascaF, SciaccaL, PandiniG, VigneriR. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-23.
70. BaroneBB, YehHC, SnyderCF, PeairsKS, SteinKB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 2008;300:2754-64.
71. MardilovichK, PankratzSL, ShawLM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14.
72. JohnsonJA, PollakM. Insulin, glucose and the increased risk of cancer in patients with type2 diabetes. Diabetologia 2010;53:2086-8.
73. PollakM. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
74. YunJ, RagoC, CheongI, PagliariniR, AngenendtP, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
75. Heikkilä K, HarrisR, LoweG, RumleyA, YarnellJ, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: Findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
76. BalkwillF. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409-16.
77. KatiyarSK, MeeranSM. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. Free Radic Biol Med 2007;42:299-310.
78. van KruijsdijkRC, van der WallE, VisserenFL. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
79. AndreasenPA, EgelundR, PetersenHH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
80. SakakibaraT, HibiK, KoikeM, FujiwaraM, KoderaY, Ito K, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005;93:799-803.
81. HilskaM, RobertsPJ, CollanYU, LaineVJ, Kössi J, Hirsimäki P, et al. Prognostic significance of matrix metalloproteinases-1,-2,-7 and-13 and tissue inhibitors of metalloproteinases-1,-2,-3 and-4 in colorectal cancer. Int J Cancer 2007;121:714-23.
82. ChoYB, LeeWY, SongSY, ShinHJ, YunSH, ChunHK. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007;38:1603-10.
83. TianM, CuiYZ, SongGH, ZongMJ, ZhouXY, ChenY, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008;8:241.
84. RoyR, YangJ, MosesMA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. JClin Oncol 2009;27:5287-97.
85. StattinP, LukanovaA, BiessyC, Söderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: Does leptin provide a link? Int J Cancer 2004;109:149-52.
86. TamakoshiK, ToyoshimaH, WakaiK, KojimaM, SuzukiK, WatanabeY, et al. Leptin is associated with an increased female colorectal cancer risk: A nested case-control study in Japan. Oncology 2005;68:454-61.
87. MunzbergH, MyersMG, Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005;8:566-70.
88. HodaMR, KeelySJ, BertelsenLS, JungerWG, DharmasenaD, BarrettKE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007;94:346-54.
89. GuiuB, PetitJM, BonnetainF, LadoireS, GuiuS, Cercueil JP, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-7.
90. SilhaJV, KrsekM, SuchardaP, MurphyLJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes(Lond) 2005;29:1308-14.
91. BeckmanJA, CreagerMA, LibbyP. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
92. HaffnerSM, LehtoS, RonnemaaT, PyoralaK, LaaksoM. Mortality from coronary heart disease in subjects with type2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEngl J Med 1998;339:229-34.
93. De VrieseAS, VerbeurenTJ, Van de VoordeJ, LameireNH, VanhouttePM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963-74.
94. KhazaeiM, MobarakehJI, RahimiAA, RazaviMR. Effect of chronic L-Arginine supplementation on aortic fatty streak formation and serum nitric oxide concentration in normal and high-cholesterol fed rabbits. Acta Physiol Hung 2012;99:87-93.
95. CerielloA, QuagliaroL, D'AmicoM, Di FilippoC, MarfellaR, NappoF, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002;51:1076-82.
96. YinJH, YangDI, KuG, HsuCY. iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem Biophys Res Commun 2000;279:30-4.
97. CookeJP, LosordoDW. Nitric oxide and angiogenesis. Circulation 2002;105:2133-5.
98. MarfellaR, EspositoK, NappoF, SiniscalchiM, SassoFC, PortogheseM, et al. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004;53:2383-91.
99. UemuraS, MatsushitaH, LiW, GlassfordAJ, AsagamiT, Lee KH, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. Circ Res 2001;88:1291-8.
100. InoguchiT, LiP, UmedaF, YuHY, KakimotoM, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 2000;49:1939-45.
101. SassoFC, TorellaD, CarbonaraO, EllisonGM, TorellaM, Scardone M, etal. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type2 diabetic patients with chronic coronary heart disease. JAm Coll Cardiol 2005;46:827-34.
102. ChouE, SuzumaI, WayKJ, OplandD, ClermontAC, Naruse K, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: Apossible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-9.
103. SassoFC, CarbonaraO, PersicoE, D'AmbrosioR, Coppola L, Nasti R, et al. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Metabolism 2003;52:675-8.
104. ZhangX, LassilaM, CooperME, CaoZ. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type1 and type2 receptors. Hypertension 2004;43:276-81.
105. ShiojimaI, WalshK. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-50.
106. KureishiY, LuoZ, ShiojimaI, BialikA, FultonD, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.